Welcome to our dedicated page for Rigel Pharmaceuticals SEC filings (Ticker: RIGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rigel Pharmaceuticals' SEC filings document the regulatory record of a Delaware biotechnology company with common stock listed on Nasdaq under RIGL. Its 8-K reports frequently furnish operating results, product revenue trends, collaboration revenue and business updates tied to TAVALISSE, GAVRETO, REZLIDHIA and development programs such as R289.
The filings also cover material agreements, license and collaboration disclosures, capital-structure information for common stock, and governance matters. Proxy materials describe shareholder voting items, board matters, executive compensation and equity awards, while material-event filings record changes affecting agreements, financial reporting and corporate governance.
Santos David A reported acquisition or exercise transactions in this Form 4 filing.
Rigel Pharmaceuticals executive David A. Santos reported an equity grant. He was awarded 19,430 shares of common stock at a price of $0.00 per share, tied to a Restricted Stock Unit award. The RSUs will vest quarterly over three years, starting on March 31, 2026, increasing his direct ownership to 62,870 shares as they vest.
Rigel Pharmaceuticals EVP & Chief Financial Officer Dean L. Schorno reported an equity award of company stock. He acquired 20,636 shares of common stock through a grant of restricted stock units at a stated price of $0.00 per share. Following this grant, he directly holds 76,337 common shares.
The award vests over time rather than all at once. The restricted stock units are scheduled to vest quarterly over three years, with the first quarterly vesting date on March 31, 2026. As each portion vests, the corresponding shares of common stock will be delivered to him.
Rigel Pharmaceuticals executive Dean L. Schorno reported a tax-related share disposition. As EVP & Chief Financial Officer, he had 3,546 shares of Rigel Pharmaceuticals common stock withheld on February 10, 2026 to cover tax obligations at a price of $34.62 per share.
After this tax-withholding disposition, he directly beneficially owned 55,701 shares of Rigel Pharmaceuticals common stock. The filing characterizes the transaction as payment of a tax liability by delivering securities, rather than an open-market sale.
Rigel Pharmaceuticals executive Raymond J. Furey disposed of 3,546 shares of common stock on February 10, 2026 to satisfy tax obligations. The tax-withholding disposition, reported under transaction code F at a share price of $34.62, left him holding 32,316 shares of Rigel common stock directly.
Rigel Pharmaceuticals executive David A. Santos reported a routine share disposition related to tax withholding. On 02/10/2026, 3,546 shares of common stock were disposed of at $34.62 per share to satisfy tax obligations associated with equity compensation. After this transaction, he directly owned 43,440 shares of Rigel common stock.
Rigel Pharmaceuticals CEO Raul R. Rodriguez reported an automatic share disposition related to taxes. On 02/10/2026, 7,607 shares of common stock were withheld at $34.62 per share in a transaction coded “F,” which indicates payment of tax liability by delivering securities.
After this tax-withholding disposition, Rodriguez directly owned 228,102 shares of Rigel Pharmaceuticals common stock. This filing reflects an administrative equity and tax event rather than an open-market purchase or sale.
Rigel Pharmaceuticals executive Lisa Rojkjaer reported a tax-related stock transaction. As EVP and Chief Medical Officer, she disposed of 3,758 shares of common stock on February 10, 2026 through a tax-withholding arrangement at $34.62 per share.
After this transaction, she directly beneficially owned 15,959 shares of Rigel Pharmaceuticals common stock. The transaction was coded as a payment of tax liability by delivering securities, which is typically associated with equity compensation events rather than an open-market sale.
State Street Corporation, a Massachusetts-based financial institution, has disclosed a passive ownership stake in Rigel Pharmaceuticals, Inc. common stock. As of the event date of 12/31/2025, State Street beneficially owned 1,091,223 shares, representing 6% of Rigel’s outstanding common stock.
State Street reports no sole voting or dispositive power over the shares. It has shared voting power over 1,064,192 shares and shared dispositive power over 1,091,223 shares, held through affiliated investment adviser subsidiaries including SSGA Funds Management, Inc. The holdings are certified as being in the ordinary course of business and not for influencing control of Rigel.
Rigel Pharmaceuticals executive David A. Santos, EVP and Chief Commercial Officer, reported a disposition of common stock. On 02/02/2026, he disposed of 5,718 shares of Rigel common stock at $36.01 per share in a transaction coded "F." After this transaction, he beneficially owned 46,986 shares, held directly. A footnote explains that this balance includes 1,000 shares acquired under the issuer's stock purchase plan.
Rigel Pharmaceuticals executive Dean L. Schorno, EVP & Chief Financial Officer, reported a Form 4 transaction involving company common stock. On 02/02/2026, 5,488 shares of common stock were disposed of in a transaction coded "F" at a price of $36.01 per share.
Following this transaction, Schorno beneficially owned 59,247 shares of Rigel common stock in direct ownership. This total includes 500 shares acquired under Rigel’s stock purchase plan, as noted in the filing’s footnote.